Get the Stockscreener App
3.27
10.66%
-0.39
After Hours:
3.27
Nls Pharmaceutics Ltd stock is traded at $3.27, with a volume of 123.83K.
It is down -10.66% in the last 24 hours and down -21.77% over the past month.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
See More
Previous Close:
$3.66
Open:
$3.58
24h Volume:
123.83K
Relative Volume:
0.60
Market Cap:
$13.16M
Revenue:
-
Net Income/Loss:
$-15.47M
P/E Ratio:
-3.8929
EPS:
-0.84
Net Cash Flow:
$-13.51M
1W Performance:
-0.61%
1M Performance:
-21.77%
6M Performance:
-53.02%
1Y Performance:
-78.96%
1-Day Range:
$3.23
$3.58
1-Week Range:
$3.1901
$3.72
52-Week Range:
$3.00
$29.08
Nls Pharmaceutics Ltd Stock (NLSP) Company Profile
Compare NLSP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NLSP
Nls Pharmaceutics Ltd
|
3.27 | 13.16M | 0 | -15.47M | -13.51M | -0.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Nls Pharmaceutics Ltd Stock (NLSP) Latest News
Preclinical Program Investigates Potential of NLS’ Dual Orexin Agonists for Narcolepsy - Sleep Review
NLS Pharmaceutics highlights preclinical program for AEX-41, AEX-2 - TipRanks
NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders - AccessWire
NLS Pharmaceutics Advances Novel Dual Orexin Drug Platform in Key Preclinical Study | NLSPW Stock News - StockTitan
NLS Pharmaceutics AG Announces Share Capital Expansion - TipRanks
ARMISTICE CAPITAL, LLC Acquires Additional Shares in NLS Pharmac - GuruFocus.com
NLS Pharmaceutics announces merger with Kadimastem - Investing.com India
NLSP stock touches 52-week low at $3.15 amid market challenges - Investing.com
500: Something went wrong - Investing.com India
Kadimastem Ltd. Faces Financial Uncertainty - TipRanks
NLS Pharmaceutics announces merger with Kadimastem By Investing.com - Investing.com UK
NLS Pharmaceutics Announces Strategic Capital Restructuring - TipRanks
What's Going On With NLS Pharmaceutics Shares Monday? - MSN
NLS and Kadimastem stocks soar following merger agreement - Yahoo Finance
NLS Pharmaceutics and Kadimastem Announce Strategic Merger - TipRanks
NLS Pharmaceutics, Kadimastem enter definitive merger agreement - Yahoo Finance
NLS Pharmaceutics stock jumps 50% on merger agreement with cell therapy firm Kadimastem - MSN
NLS Pharmaceutics and Kadimastem to merge in biotech deal By Investing.com - Investing.com Canada
Definitive Merger Agreement Reached Between NLS and Kadimastem - Sleep Review
NLS Pharmaceutics and Kadimastem to merge in biotech deal - Investing.com India
NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement - StreetInsider.com
NLSP - Insider Financial
NLS Pharmaceutics Achieves Nasdaq Compliance Milestone - TipRanks
NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements - AccessWire
NLSP stock touches 52-week low at $4 amid sharp annual decline - Investing.com
NLS Pharmaceutics Strikes Debt Forgiveness Deal - TipRanks
NLS Pharmaceutics’ $3.2 Million Common Share Offering - Global Legal Chronicle
NLS Pharmaceutics Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin Dependence - AccessWire
NLS Pharmaceutics Sees Reduced Losses Amid Financial Challenges - Yahoo Finance
(NLSP) Technical Pivots with Risk Controls - Stock Traders Daily
NLS Pharmaceutics Boosts Financial Standing with Key Moves - TipRanks
NLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance with Nasdaq Continued Listing Rules - Yahoo Finance
NLS Pharmaceutics Regains Nasdaq Compliance - TipRanks
NLS Pharmaceutics Launches New Share Purchase Warrant - TipRanks
NLS Pharmaceutics AG announced that it expects to receive $3.201614 million in funding - Marketscreener.com
NLS Pharmaceutics Shareholders Approve Agenda - TipRanks
NLS Pharmaceutics Signs Option Agreement to Acquire Rights to Aexon Labs' Assets; Shares Rise - Marketscreener.com
NLS Pharmaceutics Receives Nasdaq Compliance Extension - TipRanks
NLSP stock touches 52-week high of $4.61 amid market fluctuations - Investing.com
NLS Pharmaceutics announces 1-for-40 reverse stock split - Investing.com
NLS Pharmaceutics Ltd. Announces Expected Implementation of 1-for-40 Reverse Share Split - AccessWire
A year in review: NLS Pharmaceutics Ltd (NLSP)’s performance in the last year - US Post News
Market Highlights: NLS Pharmaceutics Ltd (NLSP) Ends on a Low Note at 0.14 - The Dwinnex
NLSP: Riding the Market Waves of Growth and Decline in 2023 - The InvestChronicle
NLS Pharmaceutics Shareholders Approve Key Measures - TipRanks
NLS Pharmaceutics Adjusts Warrants Terms - TipRanks
NLS Pharmaceutics Plans Capital Increase and Debt Restructuring - TipRanks
Nls Pharmaceutics Ltd Stock (NLSP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):